menu
    • menu
    [{"orgOrder":0,"company":"MediPharm Labs","sponsor":"European Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MediPharm Labs \/ European Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"MediPharm Labs \/ European Pharmaceutical"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"MediPharm Labs \/ McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm Labs \/ McMaster University"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabigerol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediPharm Labs \/ Not Applicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Canntab Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"MediPharm Labs \/ MediPharm Labs","highestDevelopmentStatusID":"12","companyTruncated":"MediPharm Labs \/ MediPharm Labs"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"McMaster University","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oil","sponsorNew":"MediPharm Labs \/ McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm Labs \/ McMaster University"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediPharm Labs \/ Not Applicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"MediPharm Labs","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Liquid","sponsorNew":"MediPharm Labs \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"MediPharm Labs \/ National Institutes of Health"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm Labs \/ Not Applicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Avicanna","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MediPharm Labs \/ Medipharm Labs","highestDevelopmentStatusID":"12","companyTruncated":"MediPharm Labs \/ Medipharm Labs"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabis-derived Therapy","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MediPharm Labs \/ Not Applicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabis-derived Therapy","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MediPharm Labs \/ Not Applicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediPharm Labs \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by MediPharm Labs

    Menu

    MediPharm Labs

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MediPharm Labs Launches New GMP Products to the Australian Medical Cannabis Market

                            Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...

                            Brand Name : Pink Kush

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 27, 2023

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabis-derived Therapy

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MediPharm Labs Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fi...

                            Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 31, 2023

                            Lead Product(s) : Cannabis-derived Therapy

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Avicanna

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Avicanna and Medipharm Labs Expand Strategic Manufacturing Agreement for Avicanna’s Proprietary SEDDS Techno...

                            Details : Under the agreement, Avicanna and Medipharm intend to commercialize various formulations of Avicanna’s proprietary cannabinoid-based Self-Emulsifying Drug Delivery Systems (SEDDS) technology capsules for the Canadian and international markets.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 26, 2023

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Avicanna

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study

                            Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 01, 2023

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabis-derived Therapy

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study

                            Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 01, 2023

                            Lead Product(s) : Cannabis-derived Therapy

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : $16.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC

                            Details : MediPharmto design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life’s end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., across 20 sites, to treat hospice-eligible patients dia...

                            Brand Name : T2:C100

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 09, 2022

                            Lead Product(s) : Cannabidiol,Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : $16.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabigerol,Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products

                            Details : New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.

                            Brand Name : CBG:CBD

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 05, 2022

                            Lead Product(s) : Cannabigerol,Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Cannabigerol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products

                            Details : Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 05, 2022

                            Lead Product(s) : Cannabidiol,Cannabigerol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : McMaster University

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Insomnia Treatment Study using MediPharm Labs CBD50 Product to Proceed to Phase 2 with Health Canada Consent

                            Details : McMaster University researchers using MediPharm Labs’ CBD50 formula and CBD:THC 10:2 formulation, which has the same as MediPharm Labs’ CBD25, have received a No Objection Letter from Health Canada to begin recruiting human subjects for a placebo-con...

                            Brand Name : CBD50

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 31, 2021

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : McMaster University

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            MediPharm Labs

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Tetrahydrocannabinol

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : McMaster University

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            MediPharm Labs Enters Research Agreement with McMaster University to Develop Drugs Containing Cannabis Candida...

                            Details : Three initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD (cannabidiol) drug candidates for multiple indications including Pain, Insomnia associated with Major Depression, and Uremic Pruritus.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 21, 2021

                            Lead Product(s) : Cannabidiol,Tetrahydrocannabinol

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : McMaster University

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth